Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,202 across all filing types
Latest filing 2020-12-15 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于对外投资设立合资公司暨关联交易的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement about an external investment by Lingkang Pharmaceutical Group Co., Ltd. to establish a joint venture company and related party transaction. It includes information about the investment amount, parties involved, company details, transaction pricing, governance structure, risk warnings, and independent directors' opinions. The document is regulatory in nature, disclosing a corporate transaction and related party dealings, but it does not contain financial statements, earnings data, or detailed financial analysis. It is not an annual or interim report, earnings release, or audit report. It is not a call transcript or presentation. The document is a formal announcement of a corporate investment and related party transaction, which fits best under the category of Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories.
2020-12-15 Chinese
关于对外投资设立合资公司暨关联交易的独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion from the independent directors of Lingkang Pharmaceutical Group Co., Ltd. regarding an external investment to establish a joint venture and related party transactions. It references regulatory guidelines from the China Securities Regulatory Commission and company bylaws. The content is a formal opinion on a specific transaction and related governance matters, not a full report or announcement of voting results. It does not contain financial statements or earnings data, nor is it a certification or announcement of a report publication. This fits best under Regulatory Filings (RNS) as it is a compliance-related disclosure about a related party transaction and independent director opinion.
2020-12-15 Chinese
独立董事事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement of independent directors' prior approval opinion regarding a related-party transaction and joint venture establishment. It references regulatory guidance from the China Securities Regulatory Commission and company bylaws. The content is a formal opinion letter from independent directors, not a financial report, earnings release, or management discussion. It does not contain financial data or results but is a governance-related document expressing consent on a corporate action. Therefore, it fits best under Board/Management Information (MANG) as it relates to board-level approval and governance matters.
2020-12-15 Chinese
关于子公司获得注射用奥美拉唑钠一致性评价受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding a subsidiary receiving acceptance notification from the National Medical Products Administration for a drug consistency evaluation. It is a regulatory update about product approval status and its potential impact on the company. The document is short (1158 characters) and does not contain financial statements or detailed financial data. It is not an annual or interim report, earnings release, or any detailed financial filing. It is a regulatory announcement about a product approval process, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-10 Chinese
关于控股股东股份质押的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of total shares, the risk assessment, and the impact on the company. There is no financial data, no report attached or referenced as published, and no mention of a meeting or voting results. The content is about a shareholder's share pledge transaction, which fits the category of a capital or financing update related to share pledges. Therefore, the document is best classified as a Capital/Financing Update (CAP). The document length is short and focused on this specific event, confirming it is not a full report or announcement of a report publication.
2020-12-10 Chinese
关于子公司获得药品注册批件的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding its subsidiary obtaining drug registration certificates from the National Medical Products Administration. It details the drug names, registration numbers, production details, and regulatory approvals. The document is a formal public announcement about regulatory approval for pharmaceutical products, not a financial report, earnings release, or management discussion. It does not contain financial data or analysis but is a regulatory announcement about product registration. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-12-07 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.